Procept Biorobotics Stock

Procept Biorobotics Gross Margin

The Gross Margin of Procept Biorobotics (PRCT) as of Aug 7, 2026 is 63.70 %. In the previous year, Gross Margin was 61.07 % — a change of 4.31% (higher).

Gross Margin

63.70 %

YoY

4.31%

Last updated:

Gross Margin of Procept Biorobotics is 2026 63.70 % . Gross Margin of Procept Biorobotics was 2025 61.07 % . It decreases by 4.31% higher compared to the previous year.

Procept Biorobotics's gross margin stands at 64.4%, up from 55.4% several years earlier.

Access this data via the Eulerpool API

Procept Biorobotics Stock analysis

What does Procept Biorobotics do? PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Procept Biorobotics stock

Gross Margin of Procept Biorobotics is 63.70 % in 2026.

Gross Margin of Procept Biorobotics changed from 61.07 % to 63.70 %, representing a 4.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Procept Biorobotics since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Procept Biorobotics with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Procept Biorobotics

All Key Metrics — Procept Biorobotics